Table 1 Treatment outcomes in different resistant pattern based on mutation site.
Predictor variables | Successful outcomes (n = 116)60.42% | Unsuccessful outcomes (n = 76)39.58% | Total (n = 192) (% or IQR) |
|---|---|---|---|
New cases(n = 150) | |||
True resistant : one or more WT probes are not developed and one or more corresponding MUT probes are developed(n = 94) | |||
D435V | 4(3.45) | 1(1.32) | 5(2.60) |
H445Y | 7(6.03) | 2(2.64) | 9(4.69) |
H445D | 4(3.45) | 1(1.32) | 5(2.60) |
S450L | 49(42.24) | 26(34.21) | 75(39.06) |
Inferred resistant: one or more WT probes are not developed and no MUT probes developed(n = 43) | |||
WT2 | 4(3.45) | 5(6.58) | 9(4.69) |
WT3 | 6(5.17) | 5(6.58) | 11(5.73) |
WT4 | - | 2(2.64) | 2(1.04) |
WT5 | - | 3(3.95) | 3(1.56) |
WT7 | 3(2.59) | 2(2.64) | 5(2.60) |
WT8 | 10(8.82) | 3(3.95) | 13(6.77) |
Heteroresistant : All WT probes are developed and one MUT probe developed(n = 13) | |||
D435V | 1(0.86) | 1(1.32) | 2(1.04) |
H445Y | 2(1.72) | 4(5.26) | 6(3.13) |
H445D | 1(0.86) | 1(1.32) | 2(1.04) |
S450L | 1(0.86) | 2(2.64) | 3(1.56) |
Treated cases:(n = 42) | |||
True resistant : one or more WT probes are not developed and one or more corresponding MUT probes are developed(n = 28) | |||
D435V | 1(0.86) | 2(2.64) | 3(1.56) |
H445Y | 1(0.86) | 1(1.32) | 2(1.04) |
H445D | 1(0.86) | 1(1.32) | 2(1.04) |
S450L | 14(12.07) | 7(9.21) | 21(10.94) |
Inferred resistant: one or more WT probes are not developed and no MUT probes developed (n = 8) | |||
WT2 | 2(1.72) | 1(1.32) | 3(1.56) |
WT3 | 1(0.86) | 2(2.64) | 3(1.56) |
WT4 | - | 1(1.32) | 1(0.52) |
WT7 | 1(0.86) | - | 1(0.52) |
Heteroresistant : All WT probes are developed and one MUT probe developed(n = 6) | |||
H445Y | 2(1.72) | 1(1.32) | 3(1.56) |
H445D | 1(0.86) | 1(1.32) | 2(1.04) |
S450L | - | 1(1.32) | 1(0.52) |
